Dose-response efficacy of paroxetine in preventing depressive recurrences: A randomized, double-blind study

Linda Franchini, Mariangela Gasperini, Jorge Perez, Enrico Smeraldi, Raffaella Zanardi

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: The authors evaluated and compared the efficacy of 20 mg versus 40 mg of paroxetine in a randomized, double-blind, parallel-group study during a maintenance period of 28 months. Method: Ninety-nine inpatients with recurrent, unipolar depression (DSM-IV criteria) who had at least 1 depressive episode during the 18 months preceding the index episode were openly treated with paroxetine 40 mg/day. Seventy-two subjects had a stable response (Hamilton Rating Scale for Depression score <8) to paroxetine treatment and remained in the continuation treatment as outpatients for 4 months. At the time of recovery, 68 patients were randomly assigned to 1 of the 2 maintenance treatment groups: paroxetine 20 mg or paroxetine 40 mg daily. Results: Sixty-seven patients completed the 28-month follow-up period. Seventeen (51.5%) of 33 patients in the 20-mg paroxetine regimen had a single recurrence compared with 8 (23.5%) of 34 subjects in the 40-mg dose regimen (χ2 = 5.56, p = .018). Conclusion: These data suggest that a full dose of paroxetine is recommended in unipolar patients who are at high risk for recurrent depressive episodes.

Original languageEnglish
Pages (from-to)229-232
Number of pages4
JournalJournal of Clinical Psychiatry
Volume59
Issue number5
Publication statusPublished - May 1998

Fingerprint

Paroxetine
Double-Blind Method
Recurrence
Depressive Disorder
Diagnostic and Statistical Manual of Mental Disorders
Inpatients
Outpatients
Therapeutics
Maintenance
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Franchini, L., Gasperini, M., Perez, J., Smeraldi, E., & Zanardi, R. (1998). Dose-response efficacy of paroxetine in preventing depressive recurrences: A randomized, double-blind study. Journal of Clinical Psychiatry, 59(5), 229-232.

Dose-response efficacy of paroxetine in preventing depressive recurrences : A randomized, double-blind study. / Franchini, Linda; Gasperini, Mariangela; Perez, Jorge; Smeraldi, Enrico; Zanardi, Raffaella.

In: Journal of Clinical Psychiatry, Vol. 59, No. 5, 05.1998, p. 229-232.

Research output: Contribution to journalArticle

Franchini, L, Gasperini, M, Perez, J, Smeraldi, E & Zanardi, R 1998, 'Dose-response efficacy of paroxetine in preventing depressive recurrences: A randomized, double-blind study', Journal of Clinical Psychiatry, vol. 59, no. 5, pp. 229-232.
Franchini, Linda ; Gasperini, Mariangela ; Perez, Jorge ; Smeraldi, Enrico ; Zanardi, Raffaella. / Dose-response efficacy of paroxetine in preventing depressive recurrences : A randomized, double-blind study. In: Journal of Clinical Psychiatry. 1998 ; Vol. 59, No. 5. pp. 229-232.
@article{e6613329725c4e619e85a61b18dd8981,
title = "Dose-response efficacy of paroxetine in preventing depressive recurrences: A randomized, double-blind study",
abstract = "Background: The authors evaluated and compared the efficacy of 20 mg versus 40 mg of paroxetine in a randomized, double-blind, parallel-group study during a maintenance period of 28 months. Method: Ninety-nine inpatients with recurrent, unipolar depression (DSM-IV criteria) who had at least 1 depressive episode during the 18 months preceding the index episode were openly treated with paroxetine 40 mg/day. Seventy-two subjects had a stable response (Hamilton Rating Scale for Depression score <8) to paroxetine treatment and remained in the continuation treatment as outpatients for 4 months. At the time of recovery, 68 patients were randomly assigned to 1 of the 2 maintenance treatment groups: paroxetine 20 mg or paroxetine 40 mg daily. Results: Sixty-seven patients completed the 28-month follow-up period. Seventeen (51.5{\%}) of 33 patients in the 20-mg paroxetine regimen had a single recurrence compared with 8 (23.5{\%}) of 34 subjects in the 40-mg dose regimen (χ2 = 5.56, p = .018). Conclusion: These data suggest that a full dose of paroxetine is recommended in unipolar patients who are at high risk for recurrent depressive episodes.",
author = "Linda Franchini and Mariangela Gasperini and Jorge Perez and Enrico Smeraldi and Raffaella Zanardi",
year = "1998",
month = "5",
language = "English",
volume = "59",
pages = "229--232",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "5",

}

TY - JOUR

T1 - Dose-response efficacy of paroxetine in preventing depressive recurrences

T2 - A randomized, double-blind study

AU - Franchini, Linda

AU - Gasperini, Mariangela

AU - Perez, Jorge

AU - Smeraldi, Enrico

AU - Zanardi, Raffaella

PY - 1998/5

Y1 - 1998/5

N2 - Background: The authors evaluated and compared the efficacy of 20 mg versus 40 mg of paroxetine in a randomized, double-blind, parallel-group study during a maintenance period of 28 months. Method: Ninety-nine inpatients with recurrent, unipolar depression (DSM-IV criteria) who had at least 1 depressive episode during the 18 months preceding the index episode were openly treated with paroxetine 40 mg/day. Seventy-two subjects had a stable response (Hamilton Rating Scale for Depression score <8) to paroxetine treatment and remained in the continuation treatment as outpatients for 4 months. At the time of recovery, 68 patients were randomly assigned to 1 of the 2 maintenance treatment groups: paroxetine 20 mg or paroxetine 40 mg daily. Results: Sixty-seven patients completed the 28-month follow-up period. Seventeen (51.5%) of 33 patients in the 20-mg paroxetine regimen had a single recurrence compared with 8 (23.5%) of 34 subjects in the 40-mg dose regimen (χ2 = 5.56, p = .018). Conclusion: These data suggest that a full dose of paroxetine is recommended in unipolar patients who are at high risk for recurrent depressive episodes.

AB - Background: The authors evaluated and compared the efficacy of 20 mg versus 40 mg of paroxetine in a randomized, double-blind, parallel-group study during a maintenance period of 28 months. Method: Ninety-nine inpatients with recurrent, unipolar depression (DSM-IV criteria) who had at least 1 depressive episode during the 18 months preceding the index episode were openly treated with paroxetine 40 mg/day. Seventy-two subjects had a stable response (Hamilton Rating Scale for Depression score <8) to paroxetine treatment and remained in the continuation treatment as outpatients for 4 months. At the time of recovery, 68 patients were randomly assigned to 1 of the 2 maintenance treatment groups: paroxetine 20 mg or paroxetine 40 mg daily. Results: Sixty-seven patients completed the 28-month follow-up period. Seventeen (51.5%) of 33 patients in the 20-mg paroxetine regimen had a single recurrence compared with 8 (23.5%) of 34 subjects in the 40-mg dose regimen (χ2 = 5.56, p = .018). Conclusion: These data suggest that a full dose of paroxetine is recommended in unipolar patients who are at high risk for recurrent depressive episodes.

UR - http://www.scopus.com/inward/record.url?scp=0031748107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031748107&partnerID=8YFLogxK

M3 - Article

C2 - 9632032

AN - SCOPUS:0031748107

VL - 59

SP - 229

EP - 232

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 5

ER -